Search

Conozca una prueba no invasiva para el cáncer pulmonar llamada “nariz electrónica” que está siendo investigada en Memorial Sloan Kettering.

… Monday, July 8, 2024 Detectar el  cáncer pulmonar lo antes posible ha sido durante mucho tiempo un objetivo de los especialistas de MSK, ya que les brinda a los médicos más opciones de tratamiento, lo que puede mejorar los resultados para los pacientes.    Un equipo dirigido por el cirujano torácico

Learn how people with early stage breast cancer can receive radiation therapy without the need for tattoos at Memorial Sloan Kettering Cancer Center.

… Tuesday, January 3, 2023 Memorial Sloan Kettering Cancer Center offers tattoo-less radiation therapy for early-stage breast cancer. MSK’s tattoo-less radiation uses Surface Guided Radiation Therapy that is just as accurate as radiotherapy with tattoos and can be done more quickly. The experts at Memorial

New MSK research uncovers clues about how cells control a key DNA repair protein; develops a new method for studying gene amplifications in cancer; sheds new light on tumor suppressor genes; shows MSK-IMPACT® could be used for HLA genotype screening to predict response to cellular therapies; identifies a possible strategy to overcome immune evasion in ovarian cancer; and finds strong support for telemedicine visits among cancer patients.

… Wednesday, December 18, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) uncovers clues about how cells control a key DNA repair protein; develops a new method for studying gene amplifications in cancer; sheds new light on tumor suppressor genes; shows MSK-IMPACT ® could be used for

Research at Memorial Sloan Kettering Cancer Center suggests that what’s usually considered low-risk ductal carcinoma in situ (DCIS) may still present significant risk. Two European trials comparing observation to surgical excision for women with low-risk DCIS are expected to provide important additional data.

… Thursday, June 23, 2016 The DCIS Treatment Controversy The appropriate management of women with ductal carcinoma in situ (DCIS) remains an area of ongoing controversy. DCIS is a noninvasive breast lesion diagnosed in more than 60,000 patients annually in the United States, currently accounting for 20

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors, given by the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH) organizations.

… Monday, June 22, 2020 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors to our staff, given by the American Association for Cancer Research (AACR) , the American Society of Clinical Oncology (ASCO) , and the American Society of Hematology (ASH) organizations: American

Clinically meaningful secondary cancer occurred in non-small cell lung cancer survivors, both within and beyond the thorax and over a prolonged period, according to a new study by a multidisciplinary team of lung cancer experts at MSK. The findings underscore the importance of risk-adapted, symptom-responsive survivorship care that includes evaluating heritable risk.

… Thursday, January 22, 2026 Clinically meaningful secondary cancer occurred in non-small cell lung cancer (NSCLC) survivors, both within and beyond the thorax and over a prolonged period, according to a new study by a multidisciplinary team of lung cancer experts at Memorial Sloan Kettering Cancer Center

MSK researchers presented exciting advances in medical oncology for a range of cancer types at the ESMO Congress 2025. Highlights included the latest updates on three phase 1 trials testing innovative treatment approaches for select patients with advanced solid tumors, NSCLC, and pancreatic cancer. MSK researchers also presented new insights about mismatch repair deficient solid tumors that may inform tailoring personalized treatments.

… Monday, October 20, 2025 Memorial Sloan Kettering Cancer Center (MSK) researchers presented exciting advances in medical oncology for a range of cancer types at the European Society for Medical Oncology Congress 2025 held October 17 to 21 in Berlin, Germany. Highlights included the latest updates on

In a study of patient tumor samples, researchers have found common mutations in parts of the genome that control gene regulation.

… Thursday, November 13, 2014 Summary In a study of patient tumor samples, researchers have found common mutations in parts of the genome that control gene regulation. About three billion base pairs make up the human genome. But less than 2 percent of that material contains the sequences for genes that

Results from a phase 2 clinical trial report a combination of two checkpoint inhibitor immunotherapy drugs given before melanoma surgery prevents this aggressive skin cancer from coming back. This new drug combination also has fewer side effects than other immunotherapy treatments.

… Wednesday, October 26, 2022 When Nancy Schroeder found out her melanoma had spread to her lymph nodes four years after she’d had surgery from a local dermatologist near her home in Florida, she knew she needed to go to Memorial Sloan Kettering Cancer Center (MSK) to benefit from the latest research and

Newly published results from a randomized, Phase III trial show that the drug sunitinib malate (Sutent®) is more effective than the conventional treatment given as an initial therapy for patients with advanced kidney cancer.

… Wednesday, January 10, 2007 Newly published results from a randomized, Phase III trial show that the drug sunitinib malate (Sutent ® ) is more effective than the conventional treatment given as an initial therapy for patients with advanced kidney cancer . The multicenter study, led by Robert Motzer,